Decoy Therapeutics Inc. (DCOY)vsJohnson & Johnson (JNJ)
DCOY
Decoy Therapeutics Inc.
$0.98
-7.56%
HEALTHCARE · Cap: $2.33M
JNJ
Johnson & Johnson
$282.84
-1.12%
HEALTHCARE · Cap: $682.52B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 43638698% more annual revenue ($99.33B vs $227,630). JNJ leads profitability with a 16.2% profit margin vs 0.0%. DCOY trades at a lower P/E of 0.1x. JNJ earns a higher WallStSmart Score of 54/100 (C-).
DCOY
Avoid25
out of 100
Grade: F
JNJ
Buy54
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Mega-cap, among the largest globally
Strong operational efficiency at 26.6%
Generating 6.4B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.4x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : DCOY
The strongest argument for DCOY centers on P/E Ratio, Price/Book.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.
Bear Case : DCOY
The primary concerns for DCOY are Revenue Growth, EPS Growth, Market Cap.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 43.0x leaves little room for execution misses.
Key Dynamics to Monitor
DCOY profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
DCOY carries more volatility with a beta of 0.74 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 25/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Decoy Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. The company is headquartered in Cambridge, Massachusetts.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?